The Changing Role of Medication

Slides:



Advertisements
Similar presentations
RARE Networking Webinar: “Improving Care Transitions for Patients with Mental Illnesses and Substance Use Disorders” Speakers: Paul Goering, MD Allina.
Advertisements

Schizophrenia What is schizophrenia?  Most disabling and chronic of all mental illnesses  Psychosis: type of mental illness- cannot distinguish reality.
Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
Poor Bipolar Outcome The Effect of Substance Abuse On Bipolar Disorder Phillip Long M.D.
UNIVERSITY OF JYVÄSKYLÄ OPEN DIALOGUE: Clients voices to be heard Jaakko Seikkula Seikkula, J. & Arnkil, TE (2006) Dialogical meetings in social networks.
Open Dialogues in acute crises – less medication, hospitalization and schizophrenia? Jaakko Seikkula Seikkula, J. & Arnkil TE. Dialogical meetings in social.
Managing Chronic Mental Illness in Primary Care  The “recovery” model of managing serious mental illness  Prognosis for Recovery  Tools and frameworks.
Jill Dennison Regional Lead, Western Region Schizophrenia Society of Ontario Mental illness and Seniors.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Treatment adherence: Factors, challenges, and solutions Paul R. Swaim; MEd, ALC MENTAL ILLNESS: CLOSING THE GAP BETWEEN NEEDS AND SERVICES -THE DISCONNECT.
Drug Therapy.  Although the causes of schizophrenia are still largely unknown, treatment for it focuses on lessening the type one and type two symptoms.
PARANOID SCHIZOPHRENIA By: Kayla McCuen Anna Marsh.
The Changing Role of Medication in Advancing Recovery NYAPRS Conference.
Open Dialogue. Listening to what patients and their families want Communication just didn’t happen at the time we needed it Professionals don’t always.
Severe and Persistent Mental Illness and Mothers A Mothers’ Mental Health Toolkit Project Learning Video with Dr. Joanne MacDonald Reproductive Mental.
WPA Medical Conditions That May Present with Psychosis Temporal lobe epilepsyTemporal lobe epilepsy TumorTumor StrokeStroke TraumaTrauma Endocrine/metabolic.
What is psychosis? D B Double
Managing Psychosis (NICE Guidelines 2014)
Mental disorder An introduction John Crichton Consultant Forensic Psychiatrist.
Schizophrenia: A neuro-developmental disorder of social and cognitive decline Demian Rose, MD, PhD.
 Definition: Severe, ongoing anxiety that interferes with day to day activities.  Treatment methods: medication and/ or therapy.
Open Dialogue: the future for EQUIP?
PROFESSIONAL ACTIVITY AND SCHIZOPHRENIA: ASSOCIATED FACTORS AND IMPACT IN PROGNOSIS OUERFELLI I., JOMLI R., OUERTANI A., NACEF F. DEPARTMENT OF PSYCHIATRY.
Mental Health, Mental Illness and Chronic Disease Policy CMHA National Conference August 2008 Barbara Neuwelt, CMHA, Ontario.
Update in the Treatment of Depressive Disorders Renee Lamm MD ABPN, ABAM FAPA, FAAFP.
SERUM LEVELS OF IGF-1 IN FIRST EPISODE PSYCHOSIS AND CHRONIC SCHIZOPHRENIA PATIENTS COMPARED TO HEALTHY CONTROLS E. Ntouros 1, E. Karanikas 1, P. Ntafoulis.
Mental Health Services, University of Copenhagen 1.
Schizophrenia Terrence Gault.
Shaul Lev-Ran, MD Shalvata Mental Health Center
Going back to work or to study after a first-episode psychosis : the impact of an early intervention program over 5 years Amal Abdel-Baki (1,2), Geneviève.
3 Revolutions in Psychology - Psychiatry Psychotherapeutic Drugs.
Schizophrenia Rebecca Love.
7th Grade 7.MEH.3.1. Objective 3.1  Identify resources that would be appropriate for treating common mental disorders.
3 Revolutions in Psychology - Psychiatry Psychotherapeutic Drugs.
By: DJ Kyles.  Bipolar disorder (also known as manic depression) causes serious shifts in mood, energy, thinking, and behavior– from the highs of mania.
Susan Gingerich, MSW A Brief Overview of First Episode Psychosis and A Description of the NAVIGATE Program Susan Gingerich, MSW
Schizophrenia and Related Disorders
Medication for Psychosis: Myths and Truths Demian Rose, MD, PhD UCSF Assistant Professor PREP Medical Director PREP Prevention and Recovery of Early Psychosis.
Open Dialogue in Notts Healthcare NHS Foundation Trust Simon Smith Executive Director of Local Services Corinne Hendy Peer Support Worker Anna Cheetham.
Bipolar Disorder. What is it? Definition: “previously known as manic depression - is a condition that affects your moods, which can swing from one extreme.
Myth: Depression results from a personality weakness or character flaw, and people who are depressed could just snap out of it if they tried hard enough.
PSYCHOTIC DISORDER Mental Health First Aid By Mental Health Commission of Canada, 2010.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Major Depressive Disorder
Working with people experiencing psychosis
Birth Order and Schizophrenia Study
Research methods- Clinical
CTOs and ACT: Necessary? Effective? Ethical?
Mental Health TS Conference 2017
Soteria Being with, not doing to.
Quality of Medical Care Received by Individuals with Mental Illnesses
Symptom Control and Enhancing Functioning in Schizophrenia
EMERGENCY DEPARTMENT ASSESSMENTS FOR INVOLUNTARY ADMISSION TO AN APPROVED CENTRE, AFTER IMPLEMENTATION OF MENTAL HEALTH ACT.
Falon Fiorillo & Breeanna Fournier
Section 4.4 Treating Mental Disorders Objectives
Expansion of Early Psychosis Care in U.S. Community Settings
OF PHARMACOLOGICAL TREATMENT IN PATIENTS WITH SEVERE MENTAL ILLNESS
Module 19 Mental Health Revised.
Huntington’s Disease Julia Elder.
How Open Dialogue Started
Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Mental Disease and Illness
The Challenges of Bipolar Disorders
Introduction to Psychiatry for Holy Spirit – 10th Grade
OPEN DIALOGUE: Naturalistic study designs for developing the system to reduced medication Jaakko Seikkula
Describe and Evaluate Biological Treatments for Schizophrenia
Transforming Behavioral Healthcare
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Describe and Evaluate Biological Treatments for Schizophrenia
Presentation transcript:

The Changing Role of Medication in Advancing Recovery NYAPRS Conference

Martin Harrow’s Long-Term Study of Psychotic Patients Patient Enrollment 64 schizophrenia patients 81 patients with other psychotic disorders 37 psychotic bipolar patients 28 unipolar psychotic patients 16 other milder psychotic disorders Median age of 22.9 years at index hospitalization Previous hospitalization 46% first hospitalization 21% one previous hospitalization 33% two or more previous hospitalizations Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Long-term Recovery Rates for Schizophrenia Patients 50% 40% 30% 20% Off Antipsychotics 10% On Antipsychotics 0% 2 years 4.5 years 7.5 years 10 years 15 years Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Global Adjustment of Schizophrenia Patients Worst outcomes 8 On Antipsychotics Off Antipsychotics 7 6 5 4 3 2 1 Best outcomes 2 years 4.5 years 7.5 years 10 years 15 years Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Spectrum of Outcomes in Harrow’s Study Recovered FairUniformly Poor On Antipsychotics 0.05 0.46 0.49 Off Antipsychotics 0 . 4 0.46 0.1 6 0%25%50%75%100% Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Psychotic Symptoms Over the Long Term Schizophrenia Patients Experiencing Psychotic Symptoms Over the Long Term O ff antipsychotics On Antipsychotics 100% 75% 50% 0.79 0.64 25% 0.28 0. 23 0% 10-year followup 15-year followup Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Global Adjustment of “Other Psychotic” Patients Worst outcomes 8 7 6 5 4 3 2 On Antipsychotics Off Antipsychotics 1 Best outcomes 2 years 4.5 years 7.5 years 10 years 15 years Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

Global Adjustment of All Psychotic Patients Worst outcomes 8 7 6 5 4 3 2 Schizophrenia On Meds Other Disorders On Meds Schizophrenia Off Meds Other Disorders Off Meds Best outcomes 1 0 2 years 4.5 years 7.5 years 10 years 15 years Source: Harrow M. “Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications.” Journal of Nervous and Mental Disease 195 (2007):406-14.

“In addition, global outcome for the group of patients with schizophrenia who were on antipsychotics was compared with the off- medication schizophrenia patients with similar prognostic status. Starting with the 4.5-year follow-up and extending to the 15- year follow-up, the off-medication subgroup tended to show better global outcomes at each followup.” Martin Harrow, page 411.

Five-Year Outcomes for First-Episode Psychotic Patients in Finnish Western Lapland Treated with Open-Dialogue Therapy Patients (N=75) Schizophrenia (N=30) Other psychotic disorders (N=45) Antipsychotic use Never exposed to antipsychotics Occasional use during five years Ongoing use at end of five years 67% 33% 20% Psychotic symptoms Never relapsed during five years Asymptomatic at five-year followup 67% 79% Functional outcomes at five years Working or in school Unemployed On disability 73% 7% 20% Source: Seikkula, J. “Five-year experience of first-episode nonaffective psychosis in open-dialogue approach.” Psychotherapy Research 16 (2006):214-28.